StockNews.com Begins Coverage on Check-Cap (NASDAQ:CHEK)

StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note issued to investors on Monday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Price Performance

Shares of NASDAQ:CHEK opened at $0.82 on Monday. The company has a 50 day moving average of $1.26 and a 200-day moving average of $1.77. Check-Cap has a one year low of $0.76 and a one year high of $3.52. The stock has a market cap of $4.81 million, a price-to-earnings ratio of -0.27 and a beta of 0.39.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.